Bottom line
JAFMX vs XLV: the short answer
JAFMX (Health Sciences Trust) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both mutual funds.
But JAFMX is far broader, holding 173 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
XLV is cheaper at 0.08% vs 0.99% — a difference of $91 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +4.2% for JAFMX.
Updated Nov 19, 2026
JAFMX vs XLV side by side
| JAFMX | XLV | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | John Hancock | SPDR (State Street) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.99% | 0.08% |
| Annual cost per $10k | $99 | $8 |
| 10-yr cost on $10k (prospectus) | $1,224 | $103 |
| Max front load | — | None |
| 12b-1 fee | 0% | 0.02% |
| 1-yr return | +19.5% | +14.5% |
| 5-yr return (annualized) | +4.2% | +8.1% |
| 10-yr return (annualized) | +8.8% | +9.8% |
| Best quarter | — | +14.5% |
| Worst quarter | — | −12.7% |
| Net assets (fund) | $251.3M | $40.6B |
| Number of holdings | 173 | 65 |
| Portfolio turnover | 68% | 2% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
17 of JAFMX's top 25 holdings also appear in XLV's top 25.
| Holding | JAFMX | XLV |
|---|---|---|
| Eli Lilly and Company | 14.30% | 16.51% |
| Johnson and Johnson | 6.33% | 10.64% |
| UnitedHealth Group Incorporated | 5.95% | 6.57% |
| AbbVie Inc. | 5.28% | 7.74% |
| Merck and Co. Inc. | 4.21% | 5.52% |
| Gilead Sciences Inc. | 2.95% | 2.73% |
| Thermo Fisher Scientific Inc. | 2.67% | 3.24% |
| Vertex Pharmaceuticals Incorporated | 2.38% | 2.19% |
| Bristol-Myers Squibb Company | 2.22% | 2.05% |
| Abbott Laboratories | 2.00% | 2.75% |
| Intuitive Surgical Inc. | 1.98% | 2.45% |
| Amgen Inc. | 1.90% | 3.40% |
| Stryker Corporation | 1.87% | 1.89% |
| Elevance Health Inc. | 1.63% | 1.46% |
| Danaher Corporation | 1.51% | 2.09% |
Source: SEC Form N-PORT
JAFMX top 10
- Eli Lilly and Company — 14.30%
- Johnson and Johnson — 6.33%
- UnitedHealth Group Incorporated — 5.95%
- AbbVie Inc. — 5.28%
- Merck and Co. Inc. — 4.21%
- Gilead Sciences Inc. — 2.95%
- Thermo Fisher Scientific Inc. — 2.67%
- Vertex Pharmaceuticals Incorporated — 2.38%
- Bristol-Myers Squibb Company — 2.22%
- Abbott Laboratories — 2.00%
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FAQ
What is the difference between JAFMX and XLV?
Which is cheaper, JAFMX or XLV?
Should I own both JAFMX and XLV?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.